Heyu Biological Technology Corporation
HYBT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -25.09 | -2.03 | -0.11 | 0.01 |
| FCF Yield | -7.67% | -31.02% | -20.22% | -136.71% |
| EV / EBITDA | -410.03 | -271.39 | -5.40 | -0.96 |
| Quality | ||||
| ROIC | -0.71% | -1.10% | 13.46% | 9.30% |
| Gross Margin | 6.34% | 2.59% | 65.31% | 68.58% |
| Cash Conversion Ratio | 15.53 | -1.98 | 1.10 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 231.15% | 202.70% | -29.22% | -16.15% |
| Free Cash Flow Growth | 71.49% | -13,531.76% | -107.09% | -546.00% |
| Safety | ||||
| Net Debt / EBITDA | -17.39 | 1.91 | 0.04 | -0.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 190.04 | 1.96 | -1.16 |
| Cash Conversion Cycle | 5.02 | 12.08 | -11.28 | -411.95 |